BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial

Introduction  BAY 81–8973, a full-length recombinant factor VIII for hemophilia A treatment, has been extensively evaluated in previously treated patients in the LEOPOLD (Long-Term Efficacy Open-Label Program in Severe Hemophilia A Disease) clinical trials. Aim  To assess BAY 81–8973 efficacy and sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ljung, Rolf, Chan, Anthony K. C., Glosli, Heidi, Afonja, Olubunmi, Becker, Bastian, Tseneklidou-Stoeter, Despina, Mancuso, Maria Elisa, Saulyte-Trakymiene, Sonata, Kenet, Gili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831689/
https://www.ncbi.nlm.nih.gov/pubmed/36626898
http://dx.doi.org/10.1055/s-0042-1757876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831689/
https://www.ncbi.nlm.nih.gov/pubmed/36626898
http://dx.doi.org/10.1055/s-0042-1757876

Ejemplares similares